468 completed, 115 terminated, 85 unknown, 49 recruiting. 409 Phase 2, 250 Phase 1, 110 Phase 3, 91 Phase 4, 25 Not applicable.
Follow Everolimus: new trials by email Literature Review of Everolimus trials Research Report on Everolimus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer Biospecimen Collection, Computed Tomography, Elacestrant - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 50 | 2026-12-18 | 2026-06-09 |
| Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma RVU120, Everolimus (Afinitor) tablets - Medulloblastoma Recurrent, Medulloblastoma | Phase 1 | Not yet recruiting | Bożenna Dembowska Bagińska | 48 | 2026-09-01 | 2026-10-08 |
| Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations Everolimus blinded oral capsules, Placebo - Cowden's Disease, Cowden's Syndrome | Phase 2 / Phase 3 | Not yet recruiting | Boston Children's Hospital | 60 | 2026-09-01 | 2026-06-04 |
| Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) Everolimus, Tacrolimus or Cyclosporine - Liver Allograft, Liver Diseases | Phase 3 | Recruiting | Hannover Medical School | 150 | 2026-08-19 | 2026-10-05 |
| The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy Everolimus - Epilepsy, Drug Resistant | Early Phase 1 | Recruiting | Xuanwu Hospital, Beijing | 5 | 2026-07-01 | 2026-04-07 |
| EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma Everolimus and Lenvatinib, Everolimus - Neoplasms of Bone and Articular Cartilage With Unspecified Anatomical Site | Phase 2 | Not yet recruiting | Yonsei University | 94 | 2026-07-01 | 2026-06-02 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Incyte Corporation | 60 | 2026-05-20 | 2026-10-09 |
| Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer Avutometinib, defactinib, Everolimus - Phase IB, Avutometinib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 31 | 2026-05-13 | 2026-06-29 |
| MTOR Inhibitors in Older Adults Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet - Aging | Phase 1 / Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 60 | 2026-05-11 | 2026-06-25 |
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 80 | 2026-04-23 | 2026-08-11 |
| HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial 50% reduction in the dose of MPA, Switch from MPA to a mammalian target of rapamycin inhibitor (mTORi), together with an adapted dose of tacrolimus, standard antiviral therapy along with maintenance of their initial immunosuppressive therapy. - CMV Infection | Phase 4 | Not yet recruiting | Oriol Manuel | 100 | 2026-04-01 | 2026-05-06 |
| A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies Everolimus - Vascular Malformations, Arteriovenous Malformations | Phase 2 | Not yet recruiting | Yonsei University | 67 | 2026-04-01 | 2026-03-17 |
| RESTOR: PK/PD mTORi Inhibition in Older Adults Rapamycin, Everolimus, Placebo - Aging | Early Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 194 | 2026-03-04 | 2026-06-01 |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) Everolimus (Afinitor) tablets - Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 38 | 2026-03-01 | 2026-02-27 |
| Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 700 | 2026-02-16 | 2026-09-18 |
| Adjuvant Intensification for LAR Everolimus 10 mg daily - Breast Cancer Females, Triple Negative Breast Cancer (TNBC) | Phase 3 | Not yet recruiting | Fudan University | 904 | 2026-02-01 | 2026-02-12 |
| EVR and EPO for Liver Transplant Tolerance Everolimus, Epoetin alfa - Liver Transplant | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2026-01-21 | 2026-04-06 |
| Sapu003 in Advanced mTOR-sensitive Solid Tumors Sapu003, Exemestane 25 MG - Breast Cancer Metastatic, Renal Cell Carcinoma (RCC) | Phase 1 | Recruiting | SAPU NANO (US) LLC | 27 | 2025-12-15 | 2026-01-27 |
| Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women Everolimus, Placebo, Resistance training - Healthy, Osteopenia | Phase 2 | Recruiting | Odense University Hospital | 148 | 2025-10-20 | 2026-04-06 |
| Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Sirolimus for injection (albumin bound), Octreotide long-acting injection, Everolimus - Gastroenteropancreatic Neuroendocrine Tumors | Phase 2 / Phase 3 | Recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 298 | 2025-08-29 | 2026-04-24 |
Showing 20 of 801. Sign in to see all of them.
Breast Neoplasms (107) · Carcinoma, Renal Cell (73) · Neoplasm Metastasis (48) · Neoplasms (37) · Neuroendocrine Tumors (35) · Kidney Neoplasms (27) · Recurrence (20) · Tuberous Sclerosis (18) · Carcinoma, Non-Small-Cell Lung (17) · Prostatic Neoplasms (16) · Lymphoma (15) · Triple Negative Breast Neoplasms (15) · Carcinoma, Hepatocellular (14) · Glioblastoma (14) · Head and Neck Neoplasms (14)
Novartis Pharmaceuticals (135) · M.D. Anderson Cancer Center (35) · Dana-Farber Cancer Institute (19) · Memorial Sloan Kettering Cancer Center (16) · Emory University (13) · Fudan University (11) · National Cancer Institute (NCI) (11) · Mayo Clinic (10) · SCRI Development Innovations, LLC (10) · Alliance for Clinical Trials in Oncology (8) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Novartis (7) · University of California, San Francisco (7) · Asan Medical Center (5) · Children's Hospital Medical Center, Cincinnati (5)
United States (433) · Germany (117) · France (116) · Italy (95) · Spain (88) · United Kingdom (70) · Netherlands (63) · South Korea (63) · Belgium (58) · Canada (53) · China (53) · Australia (51) · Brazil (45) · Taiwan (41) · Switzerland (40)
Ingrid Mayer, MD (3) · Sandy Feng, MD, PhD (3) · Thomas E. Witzig, MD (3) · Adam Konopka, PhD (2) · Amado Zurita, MD (2) · Amy Tiersten, MD (2) · Chandrashekhar Kubal, MD (2)
PMID 37146227, PMID 19192962, PMID 29023494, PMID 21730275, PMID 25682485, PMID 30053159, PMID 30231851, PMID 30312541, PMID 33451345, PMID 33560090, PMID 39356039, PMID 39382091, PMID 39821757, PMID 40197799, PMID 42853965, PMID 11583941, PMID 15623621, PMID 15868910, PMID 16951235, PMID 17192769, PMID 18279419, PMID 18360262, PMID 18653228, PMID 18793527, PMID 19047305, PMID 19380449, PMID 19497063, PMID 19549709, PMID 19687332, PMID 19744284, PMID 19745764, PMID 19790150, PMID 20050127, PMID 20142598, PMID 20166206, PMID 20194812, PMID 20229590, PMID 20231677, PMID 20368560, PMID 20380712, PMID 20564157, PMID 20581392, PMID 20630061, PMID 20864273, PMID 20871262, PMID 21047224, PMID 21079958, PMID 21107682, PMID 21135857, PMID 21306238
2009 (16), 2008 (12), 2014 (7), 2023 (7), P30CA015083 (6), 2016 (5), 2025 (4), U10CA032102 (4), U10CA180821 (4), 2005 (3), 2015 (3), 2018 (3), 2019 (3), P30CA016672 (3), P30CA043703 (3)